Mortality and cancer incidence in carriers of constitutional t(11;22)(q23;q11) translocations: A prospective study
Authors:
- Minouk J SchoemakerMSMinouk J Schoemaker
- Michael E JonesMJMichael E Jones
- the UK Clinical Cytogenetics GroupTGthe UK Clinical Cytogenetics Group
- Anthony J SwerdlowASAnthony J Swerdlow
Open Access
- 29 November 2018
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 145 (6) , 1493-1498
Abstract
The constitutional t(11;22)(q23;q11) translocation is the only recurrent non‐Robertsonian translocation known in humans. Carriers are phenotypically normal and are usually referred for cytogenetic testing because of multiple miscarriages, infertility, or having aneuploidy in offspring. A breast cancer predisposition has been suggested, but previous studies have been small and had methodological shortcomings. We therefore conducted a long‐term prospective study of cancer and mortality risk in carriers. We followed 65 male and 101 female carriers of t(11;22)(q23;q11) diagnosed in cytogenetic laboratories in Britain during 1976–2005 for cancer and deaths for an average of 21.4 years per subject. Standardised mortality (SMR) and incidence (SIR) ratios were calculated comparing the numbers of observed events with those expected from national age‐, sex‐, country‐ and calendar‐period‐specific population rates. Cancer incidence was borderline significantly raised for cancer overall (SIR = 1.56, 95% CI: 0.98–2.36, n = 22), and significantly raised for invasive breast cancer (SIR = 2.74, 95% CI: 1.18–5.40, n = 8) and in situ breast cancer (SIR = 13.0, 95% CI: 3.55–33.4, n = 4). Breast cancer risks were particularly increased at ages in situ). Mortality was borderline significantly raised for breast cancer (SMR = 4.82, 95% CI: 0.99–14.1) but not significantly raised for other cancers or causes. Individuals diagnosed with t(11;22)(q23;q11) appear to be at several‐fold increased breast cancer risk, with the greatest risks at premenopausal ages. Further research is required to understand the genetic mechanism involving 11q23 and 22q11 and there may be a need for enhanced breast cancer surveillance among female carriers.Keywords
Funding Information
- The Medical Research Council and Minouk Schoemaker and Michael Jones are funded by Breast Cancer Now
- The Institute of Cancer Research acknowledges NHS funding to the Royal Marsden/ICR NIHR Biomedical Research Centre
This publication has 21 references indexed in Scilit:
- Risk of breast cancer not increased in translocation 11;22 carriers: Analysis of 80 pedigreesAmerican Journal of Medical Genetics Part A, 2009
- Incidence of non-age-dependent chromosomal abnormalities: a population-based study on 88965 amniocentesesEuropean Journal of Human Genetics, 2009
- High incidence of familial breast cancer segregates with constitutional t(11;22)(q23;q11)Genes, Chromosomes and Cancer, 2006
- Prevalence of chromosomal abnormalities in phenotypically normal and fertile adult males: large-scale survey of over 10 000 sperm donor karyotypesHuman Reproduction, 2006
- Population‐based study of cancer among carriers of a constitutional structural chromosomal rearrangementGenes, Chromosomes and Cancer, 2005
- A unique case of der(11)t(11;22),-22 arising from 3:1 segregation of a maternal t(11;22) in a family with co-segregation of the translocation and breast cancerPrenatal Diagnosis, 2005
- AT-Rich Palindromes Mediate the Constitutional t(11;22) TranslocationThe American Journal of Human Genetics, 2001
- Tightly Clustered 11q23 and 22q11 Breakpoints Permit PCR-Based Detection of the Recurrent Constitutional t(11;22)The American Journal of Human Genetics, 2000
- Age at first birth, parity and risk of breast cancer: A meta‐analysis of 8 studies from the nordic countriesInternational Journal of Cancer, 1990
- Simple exact analysis of the standardised mortality ratio.Journal of Epidemiology and Community Health, 1984